Identification of antipsychotic drug fluspirilene as a potential anti-glioma stem cell drug
Glioma stem cell (GSC)-targeted therapy is expected to be one of the most innovative approaches to treat patients with glioblastoma (GBM). A number of the drugs that restrain the signaling pathway essential for GSC maintenance have been under clinical trials. Here, we identified fluspirilene, a traditional antipsychotic drug, as a GSC-targeting agent, selected from thousands of existing drugs, and investigated its therapeutic effects against GBM with the purpose of drug repositioning. To develop novel therapeutics targeting GSCs, we initially screened drug libraries for small-molecule compounds showing a greater efficacy, compared to that of controls, in inhibiting the proliferation and survival of different GSC lines using cell proliferation assay. Drugs already reported to show therapeutic effects against GBM or those under clinical trials were excluded from subsequent screening. Finally, we found three drugs showing remarkable antiproliferative effects on GSCs at low concentrations and investigated their therapeutic effects on GSCs, glioma cell lines, and in a GBM mouse model. Of the three compounds, fluspirilene demonstrated a significant inhibitory effect on the proliferation and invasion of glioma cells as well as in the model mice treated with the drug. These effects were associated with the inactivation of the signal transducer and activator of transcription 3 (STAT3). Redeveloping of fluspirilene is a promising approach for the treatment of GBM.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Oncotarget - 8(2017), 67 vom: 19. Dez., Seite 111728-111741 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dong, Yu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Drug repositioning |
|---|
| Anmerkungen: |
Date Revised 15.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.18632/oncotarget.22904 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM280021879 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM280021879 | ||
| 003 | DE-627 | ||
| 005 | 20240315232432.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.18632/oncotarget.22904 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1330.xml |
| 035 | |a (DE-627)NLM280021879 | ||
| 035 | |a (NLM)29340087 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dong, Yu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Identification of antipsychotic drug fluspirilene as a potential anti-glioma stem cell drug |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 15.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Glioma stem cell (GSC)-targeted therapy is expected to be one of the most innovative approaches to treat patients with glioblastoma (GBM). A number of the drugs that restrain the signaling pathway essential for GSC maintenance have been under clinical trials. Here, we identified fluspirilene, a traditional antipsychotic drug, as a GSC-targeting agent, selected from thousands of existing drugs, and investigated its therapeutic effects against GBM with the purpose of drug repositioning. To develop novel therapeutics targeting GSCs, we initially screened drug libraries for small-molecule compounds showing a greater efficacy, compared to that of controls, in inhibiting the proliferation and survival of different GSC lines using cell proliferation assay. Drugs already reported to show therapeutic effects against GBM or those under clinical trials were excluded from subsequent screening. Finally, we found three drugs showing remarkable antiproliferative effects on GSCs at low concentrations and investigated their therapeutic effects on GSCs, glioma cell lines, and in a GBM mouse model. Of the three compounds, fluspirilene demonstrated a significant inhibitory effect on the proliferation and invasion of glioma cells as well as in the model mice treated with the drug. These effects were associated with the inactivation of the signal transducer and activator of transcription 3 (STAT3). Redeveloping of fluspirilene is a promising approach for the treatment of GBM | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a drug repositioning | |
| 650 | 4 | |a drug screening | |
| 650 | 4 | |a glioblastoma | |
| 650 | 4 | |a glioma stem cell | |
| 700 | 1 | |a Furuta, Takuya |e verfasserin |4 aut | |
| 700 | 1 | |a Sabit, Hemragul |e verfasserin |4 aut | |
| 700 | 1 | |a Kitabayashi, Tomohiro |e verfasserin |4 aut | |
| 700 | 1 | |a Jiapaer, Shabierjiang |e verfasserin |4 aut | |
| 700 | 1 | |a Kobayashi, Masahiko |e verfasserin |4 aut | |
| 700 | 1 | |a Ino, Yasushi |e verfasserin |4 aut | |
| 700 | 1 | |a Todo, Tomoki |e verfasserin |4 aut | |
| 700 | 1 | |a Teng, Lei |e verfasserin |4 aut | |
| 700 | 1 | |a Hirao, Atsushi |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Shi-Guang |e verfasserin |4 aut | |
| 700 | 1 | |a Nakada, Mitsutoshi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oncotarget |d 2010 |g 8(2017), 67 vom: 19. Dez., Seite 111728-111741 |w (DE-627)NLM199620113 |x 1949-2553 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2017 |g number:67 |g day:19 |g month:12 |g pages:111728-111741 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.18632/oncotarget.22904 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2017 |e 67 |b 19 |c 12 |h 111728-111741 | ||